Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of INDV-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder

NCT06384157 is registered in ClinicalTrials.gov with Indivior Inc. as lead sponsor.

NCT NCT06384157
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06384157 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of INDV-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder
Lead sponsor
Indivior Inc.
Phase
Phase 2
Overall status
Completed
Start date
June 10, 2024
Completion date
November 3, 2025
Enrollment
300 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

opioid use disorder